CeriBell (NASDAQ:CBLL) Earns “Buy” Rating from BTIG Research

CeriBell (NASDAQ:CBLL)‘s stock had its “buy” rating reissued by BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $30.00 price objective on the stock. BTIG Research’s target price suggests a potential upside of 46.84% from the stock’s previous close.

Several other equities research analysts also recently issued reports on CBLL. Canaccord Genuity Group increased their price objective on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Raymond James Financial began coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. JPMorgan Chase & Co. decreased their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

CeriBell Price Performance

CBLL stock opened at $20.43 on Wednesday. CeriBell has a one year low of $10.01 and a one year high of $26.04. The firm has a 50-day moving average of $20.74 and a two-hundred day moving average of $15.50. The firm has a market capitalization of $757.95 million, a PE ratio of -13.53 and a beta of 1.02. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The business had revenue of $22.59 million during the quarter, compared to the consensus estimate of $21.78 million. On average, analysts forecast that CeriBell will post -2.46 earnings per share for the current year.

Insider Activity at CeriBell

In other CeriBell news, Director William W. Burke sold 32,728 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $22.02, for a total transaction of $720,670.56. Following the completion of the sale, the director owned 17,391 shares of the company’s stock, valued at $382,949.82. This represents a 65.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Xingjuan Chao sold 79,000 shares of CeriBell stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $21.27, for a total transaction of $1,680,330.00. Following the completion of the transaction, the chief executive officer directly owned 741,248 shares in the company, valued at approximately $15,766,344.96. This represents a 9.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 375,212 shares of company stock valued at $7,306,950. Insiders own 20.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. grew its position in shares of CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares during the last quarter. CWM LLC grew its holdings in CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares during the last quarter. Tower Research Capital LLC TRC increased its position in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CeriBell during the third quarter worth approximately $33,000. Finally, Sei Investments Co. grew its stake in shares of CeriBell by 7.1% in the third quarter. Sei Investments Co. now owns 50,454 shares of the company’s stock worth $580,000 after acquiring an additional 3,365 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.